Radiochemotherapy-induced elevations of plasma HMGB1 levels predict therapeutic responses in cancer patients - Sorbonne Université
Article Dans Une Revue OncoImmunology Année : 2021

Radiochemotherapy-induced elevations of plasma HMGB1 levels predict therapeutic responses in cancer patients

Guido Kroemer
Oliver Kepp

Résumé

High mobility group B1 (HMGB1) is a protein that is released from dying cancer cells in the context of immunogenic cell death (ICD). A recent study performed on patients with head and neck squamous cell carcinomas (HNSCC) reports that a chemoradiotherapy-induced increase in circulating HMGB1 levels predicts favorable outcome, echoing prior studies on neoadjuvant treatment of breast and rectal cancer in which the dynamics of HMGB1 plasma levels also have prognostic value. Hence, a therapy-induced rise in HMGB1 may be interpreted as a clinical sign of ICD and therapeutic response.

Domaines

Cancer
Fichier principal
Vignette du fichier
2162402X.2021.pdf (812.75 Ko) Télécharger le fichier
Origine Publication financée par une institution

Dates et versions

hal-03467607 , version 1 (06-12-2021)

Identifiants

Citer

Guido Kroemer, Oliver Kepp. Radiochemotherapy-induced elevations of plasma HMGB1 levels predict therapeutic responses in cancer patients. OncoImmunology, 2021, 10 (1), ⟨10.1080/2162402x.2021.2005859⟩. ⟨hal-03467607⟩
103 Consultations
27 Téléchargements

Altmetric

Partager

More